论文部分内容阅读
目的:探讨硫糖铝、兰索拉唑、莫沙必利联合治疗胃食管反流病的临床疗效。方法:根据大样本随机、对照、双盲试验原则,我们从样本库中随机抽取了50例患者数据且随机分为两组,观察组和对照组,各25例。两组患者在年龄、性别、疾病史等方面均无显著性差异。观察组治疗方法为:硫糖铝1.0 g,3次/d,饭前1 h嚼服;兰索拉唑30 mg,1次/d,饭前30 min服用;莫沙必利5 mg,3次/d,饭前30 min服用。对照组为:奥美拉唑20 mg,2次/d,饭前30 min服用;多潘立酮10 mg,3次/d,饭前30 min服用。两组均以6 w为1个疗程,疗程结束后我们综合对比了两组的临床疗效(烧心、反酸、胸骨后痛、吞咽不适等)及不良反应,并复查胃镜。结果:观察组的临床有效率为96%,明显高于对照组的临床有效率74%,该结果具有统计学意义,但两组差异无统计学意义(P>0.05)。胃镜下食管炎愈合及炎症改善情况:治疗组86%,对照组70%,两者比较差异有显著性(P<0.05),但两组差异无统计学意义(P>0.05)。结论:硫糖铝、兰索拉唑、莫沙必利联合治疗反流性食管炎的临床疗效明显优于非联合用药的疗效,值得进一步在临床上推广和应用。
Objective: To investigate the clinical efficacy of sucralfate, lansoprazole and mosapride in the treatment of gastroesophageal reflux disease. Methods: According to the principle of randomized, controlled and double-blind trial of large sample, we randomly selected 50 patients from the sample database and randomly divided them into two groups, the observation group and the control group, with 25 cases each. There was no significant difference between the two groups in terms of age, gender, disease history and so on. The observation group was treated with sucralfate 1.0 g three times a day for 1 h before meal, lansoprazole 30 mg once daily for 3 min, and mosapride 5 mg 3 Times / d, taking 30 min before meals. The control group was treated with omeprazole 20 mg twice daily for 30 min before meals and domperidone 10 mg 3 times daily for 30 min. Both groups were 6 w for a course of treatment, after the end of the course of our comprehensive comparison of the two groups of clinical efficacy (heartburn, acid reflux, sore throat, swallowing discomfort, etc.) and adverse reactions, and review of gastroscopy. Results: The clinical effective rate in the observation group was 96%, which was significantly higher than that in the control group (74%). The results were statistically significant, but there was no significant difference between the two groups (P> 0.05). Endoscopic esophagitis healing and improvement of inflammation: the treatment group 86%, 70% of the control group, the difference was significant (P <0.05), but there was no significant difference between the two groups (P> 0.05). Conclusion: The clinical efficacy of sucralfate, lansoprazole and mosapride in the treatment of reflux esophagitis is significantly better than that of non-combination therapy, which is worth further promotion and application in clinic.